Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.31 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.31 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.31 |
| ▸ | NQO2 | P16083 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | SMC2 | O95347 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.31 |
| ▸ | SMC1A | Q14683 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.31 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18148031 | 0.85 | TSHR (0.35) | LMNAKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL18148199 | 0.84 | ACLY (0.38) | LMNAMEN1KMT2AMAP2K2MAP2K1 | |
| SCHEMBL18148033 | 0.80 | HDAC1 (0.36) | LMNAMEN1KMT2ARECQLALDH1A1 | |
| SCHEMBL18147950 | 0.80 | LMNA (0.36) | LMNAMEN1KMT2ARECQLALDH1A1 | |
| SCHEMBL18148041 | 0.78 | LMNA (0.37) | LMNAMEN1KMT2AMAP2K2MAP2K1 | |
| SCHEMBL18148044 | 0.78 | LMNA (0.37) | LMNAMEN1KMT2AMAP2K2MAP2K1 | |
| SCHEMBL18163759 | 0.76 | CNKSR1 (0.38) | LMNAMEN1KMT2AMAP2K2MAP2K1 | |
| SCHEMBL18147976 | 0.76 | LMNA (0.36) | LMNAMEN1KMT2AMAP2K2MAP2K1 | |
| SCHEMBL18147963 | 0.73 | PIK3CA (0.40) | LMNAALDH1A1 | |
| SCHEMBL18148224 | 0.69 | MAPT (0.42) | LMNAKDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227356-B2 | Compounds, compositions and methods for inhibiting CNKSR1 | PHUSIS THERAPEUTICS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-10227356-B2 | Compounds, compositions and methods for inhibiting CNKSR1 | PHUSIS THERAPEUTICS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20160304533-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR INHIBITING CNKSR1 | PHUSIS THERAPEUTICS, INC. (US) | 2016-10-20 | — | — | US | disclosed |
| US-20160304533-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR INHIBITING CNKSR1 | PHUSIS THERAPEUTICS, INC. (US) | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227356-B2 | Compounds, compositions and methods for inhibiting CNKSR1 | CNKSR1, CAMKK1, CNR1 | LMNA 1703/4885MEN1 2360/4885KMT2A 2356/4885 |
| US-20160304533-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR INHIBITING CNKSR1 | CNKSR1, CAMKK1, CNR1 | LMNA 1703/4885MEN1 2360/4885KMT2A 2356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.